Market News

EPS for Sucampo Pharmaceuticals, Inc. (SCMP) Expected At $0.34; Welch & Forbes Has Cut Marathon Pete (MPC) Position

Welch & Forbes Llc decreased Marathon Pete Corp (MPC) stake by 29.08% reported in 2017Q3 SEC filing. Welch & Forbes Llc sold 7,600 shares as Marathon Pete Corp (MPC)’s stock rose 5.52%. The Welch & Forbes Llc holds 18,537 shares with $1.04 million value, down from 26,137 last quarter. Marathon Pete Corp now has $31.03 billion valuation. The stock increased 1.67% or $1.05 during the last trading session, reaching $63.84. About 4.87M shares traded or 25.19% up from the average. Marathon Petroleum Corporation (NYSE:MPC) has risen 46.20% since February 10, 2017 and is uptrending. It has outperformed by 29.50% the S&P500.

Analysts expect Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report $0.34 EPS on March, 14.They anticipate $0.34 EPS change or 50.00% from last quarter’s $0.68 EPS. SCMP’s profit would be $16.01M giving it 13.24 P/E if the $0.34 EPS is correct. After having $0.27 EPS previously, Sucampo Pharmaceuticals, Inc.’s analysts see 25.93% EPS growth. It closed at $18 lastly. It is down 5.30% since February 10, 2017 and is downtrending. It has underperformed by 22.00% the S&P500.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company has market cap of $847.54 million. The company's marketed product includes AMITIZA , a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. It currently has negative earnings. The Company’s product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

Among 13 analysts covering Sucampo Pharma (NASDAQ:SCMP), 4 have Buy rating, 0 Sell and 9 Hold. Therefore 31% are positive. Sucampo Pharma had 46 analyst reports since August 6, 2015 according to SRatingsIntel. On Wednesday, April 20 the stock rating was upgraded by Mizuho to “Buy”. The company was maintained on Thursday, October 12 by UBS. WallachBeth Capital maintained the stock with “Hold” rating in Thursday, August 27 report. Mizuho maintained the shares of SCMP in report on Monday, January 18 with “Neutral” rating. Leerink Swann downgraded Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Tuesday, January 2 to “Market Perform” rating. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Hold” rating given on Thursday, August 4 by Jefferies. The rating was reinitiated by Roth Capital on Thursday, October 29 with “Buy”. The rating was downgraded by UBS to “Hold” on Friday, January 5. Nomura downgraded Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Friday, January 26 to “Neutral” rating. WallachBeth Capital maintained the shares of SCMP in report on Thursday, August 6 with “Hold” rating.

Since September 11, 2017, it had 0 insider purchases, and 3 selling transactions for $24.83 million activity. Shares for $825,000 were sold by Kiener Peter A. 1.00 million Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) shares with value of $12.00 million were sold by Ueno Ryuji. Kuno Sachiko sold $12.00 million worth of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Monday, September 11.

Investors sentiment increased to 1.65 in Q3 2017. Its up 0.32, from 1.33 in 2017Q2. It is positive, as 14 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 31 funds opened positions while 58 raised stakes. 29.83 million shares or 20.72% more from 24.71 million shares in 2017Q2 were reported. Advisory Services Ntwk Limited Liability Corporation invested in 0% or 195 shares. Stifel Corp reported 11,760 shares. First Tru Advsrs Ltd Partnership holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 19,858 shares. Wellington Mngmt Gru Ltd Liability Partnership accumulated 0% or 78,864 shares. Moreover, Trexquant Investment Limited Partnership has 0.03% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Moreover, Mason Street Lc has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 6,367 shares. Rhumbline Advisers holds 50,350 shares or 0% of its portfolio. Sei Invs reported 7,800 shares. Moreover, Schwab Charles Inv Incorporated has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 294,181 shares. Jefferies stated it has 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Moreover, Ativo Mgmt Ltd Liability Corp has 0.4% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Affinity Invest Advsr Limited Liability Corp owns 23,829 shares or 0.03% of their US portfolio. Connor Clark & Lunn Mgmt Ltd owns 10,025 shares or 0% of their US portfolio. Lsv Asset Management stated it has 2.47M shares or 0.05% of all its holdings. Pinebridge L P stated it has 3,120 shares.

Investors sentiment decreased to 0.91 in Q3 2017. Its down 0.14, from 1.05 in 2017Q2. It fall, as 52 investors sold MPC shares while 292 reduced holdings. 85 funds opened positions while 227 raised stakes. 380.18 million shares or 0.85% less from 383.45 million shares in 2017Q2 were reported. Frontfour Capital Grp Ltd Limited Liability Company, a Connecticut-based fund reported 9,842 shares. Regions Financial holds 0.02% or 36,391 shares in its portfolio. Foster & Motley has 16,575 shares for 0.16% of their portfolio. The Michigan-based Azimuth Cap Mgmt Limited Com has invested 0.05% in Marathon Petroleum Corporation (NYSE:MPC). M&R Mgmt Inc stated it has 1,042 shares or 0.01% of all its holdings. Monroe Commercial Bank And Trust Mi holds 5,784 shares. Hancock accumulated 267,495 shares. Bluecrest Mngmt, a Guernsey-based fund reported 324,266 shares. Blair William And Com Il holds 35,568 shares or 0.01% of its portfolio. Calamos Wealth Mgmt Ltd Liability Corp holds 0.36% or 45,695 shares. Kornitzer Mngmt Ks reported 165,000 shares or 0.16% of all its holdings. Wilen Inv stated it has 38,148 shares or 1.29% of all its holdings. Institute For Wealth holds 0.28% of its portfolio in Marathon Petroleum Corporation (NYSE:MPC) for 15,117 shares. 1.02 million are owned by Great West Life Assurance Can. Wealthtrust reported 0.01% of its portfolio in Marathon Petroleum Corporation (NYSE:MPC).

Since September 14, 2017, it had 0 insider purchases, and 5 sales for $7.73 million activity. Palmer C. Michael had sold 11,450 shares worth $607,079. The insider Nichols Rodney P. sold 6,374 shares worth $413,864. On Thursday, December 14 the insider Kelley Thomas M. sold $2.31M.

Welch & Forbes Llc increased Vanguard Intl Equity Index F (VGK) stake by 9,280 shares to 31,965 valued at $1.86M in 2017Q3. It also upped First Tr Exchange Traded Fd (FTSL) stake by 39,790 shares and now owns 314,060 shares. Chevron Corp New (NYSE:CVX) was raised too.

Among 19 analysts covering Marathon Petroleum Corp (NYSE:MPC), 12 have Buy rating, 1 Sell and 6 Hold. Therefore 63% are positive. Marathon Petroleum Corp had 74 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, November 1 by UBS. The firm has “Buy” rating given on Tuesday, February 9 by Deutsche Bank. The rating was maintained by Deutsche Bank with “Buy” on Friday, December 4. The firm has “Buy” rating by Cowen & Co given on Tuesday, October 17. Wells Fargo downgraded the stock to “Sell” rating in Monday, February 5 report. Credit Suisse maintained the stock with “Buy” rating in Thursday, July 13 report. The firm has “Market Perform” rating by Wells Fargo given on Wednesday, September 6. The stock of Marathon Petroleum Corporation (NYSE:MPC) earned “Buy” rating by RBC Capital Markets on Wednesday, December 20. On Tuesday, November 14 the stock rating was maintained by Barclays Capital with “Overweight”. The company was upgraded on Monday, August 24 by Vetr.

Leave a Reply

Your email address will not be published. Required fields are marked *